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A B S T R A C T
Ethyl pyruvate (EP) has been increasingly appreciated as an anti-inﬂammatory and neuroprotective
agent with potent pharmacological properties relevant for treatment of various CNS disorders. Microglial
cells seem to be particularly sensitive to its effects. In this study, microglial cells were exposed to EP for
relatively short periods (10–120 min) and inﬂammatory properties of the cells were determined after
24 h of cultivation. Application of EP in the short-term periods inhibited production of interleukin-6,
tumor necrosis factor and nitric oxide in microglial cells. At the same time, the effects on cell viability,
reactive oxygen species generation and expression of F4/80 and CD40 of microglial cells were minor.
NFkB activation was not affected by EP in the cells during the short exposures, thus implying that the
observed effect of EP on cytokine and nitric oxide generation was performed in NFkB independent way.
Importantly, effects of the short term EP treatment on microglial cells were detected by a real time cell
analysis, as well. The observed ability of EP to affect microglial cell function after relatively short time of
exposure is relevant for its therapeutic potential against inﬂammatory disorders of the CNS.
 2015 Elsevier Masson SAS. All rights reserved.
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Microglial cells are involved in pathogenesis of a number of
inﬂammation-related disorders of the CNS, including multiple
sclerosis (MS), Parkinson’s disease (PD), Alzheimer’s disease (AD)
and stroke [1–4]. While microglia is generally performing
protective activity in the CNS, it is shifted toward pro-inﬂamma-
tory effector phenotype in chronic inﬂammatory, autoimmune and
neurodegenerative CNS diseases [4,5]. Pro-inﬂammatory microglia
produces various inﬂammatory and neurotoxic mediators, includ-
ing cytokines, such as tumor necrosis factor (TNF), interleukin (IL)-
6 and IL-1b and reactive nitrogen and oxygen species, such as nitric
oxide (NO) and it actively participates in CNS tissue destruction
[1,3]. Also, inﬂammatory microglia increases expression of
antigen-presentation related molecules, including CD40, which
allows it to efﬁciently present antigens to T cells and thus to further
contribute to neuroinﬂammation [1,5]. Consequently, down-
regulation of pro-inﬂammatory microglial activity has been shown
beneﬁcial in the treatment of the CNS disorders [3,5].* Corresponding author at: Institute for Biological Research ‘‘Sinisˇa Stankovic´’’,
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0753-3322/ 2015 Elsevier Masson SAS. All rights reserved.Ethyl pyruvate (EP) is a potent redox active compound. It forms
Michael-type adducts with thiols and activates Nrf2 in astrocytes,
and inhibits NFkB-dependent transcription in different cell types,
including LPS-stimulated microglial BV2 cells and macrophage-
like RAW 264.7 cells [6–9]. Anti-inﬂammatory and neuroprotec-
tive effects of EP have been observed in animal models of sepsis,
uveitis, and asthma [10–12]. EP has been effective also against
different neurological insults, such as ischemia/reperfusion [13],
intracerebral hemorrhage-induced brain injury [14], traumatic
brain injury [15], 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
[16], LPS [17], and 3-nitropropionic acid [18]. Also, we have
recently shown that EP potently ameliorates of experimental
autoimmune encephalomyelitis (EAE), an animal model of MS
[19].
The aim of our current study was to compare the effects of
short-term (10 –120 min) and long time (24 h) exposure of
microglial cells to EP. The inﬂuence of EP on production of pro-
inﬂammatory cytokines (IL-6, and TNF), generation of NO and
expression of CD40 and F4/80 in BV2 cells was determined. Also,
effect of short-time exposure to EP on NFkB signaling in these cells
was examined. It appears that cytokine and NO production, but not
CD40 and F4/80 expression in microglial cells is sensitive to short-
term exposure to EP. The observed effects are not paralleled with
inhibition of NFkB signaling or with inhibition of reactive oxygen
species generation.
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2.1. Cell cultures and reagents
Unless speciﬁcally stated chemicals used in the experiments
were from Sigma-Aldrich (St. Louis, MO). BV2 cells were grown and
cultured in RPMI-1640 culture medium (PAA Laboratories,
Pasching, Austria) that was supplemented with 5% heat-inacti-
vated fetal calf serum and at 37 8C in a humidiﬁed atmosphere
containing 5% CO2. For the treatments, BV2 cells were seeded at
3  105/ml/well in 24-well plates (Sarstedt, Pasching, Austria). BV2
cells were stimulated with 10 ng/ml recombinant mouse interfer-
on-g (IFN-g) and 100 ng/ml lipopolyssacharide (LPS) and treated
with various concentrations of ethyl pyruvate (EP).
2.2. Crystal violet assay
Viability of BV2 was assessed by crystal-violet (CV) test. At the
end of the treatment, cells were washed with PBS to remove non-
adherent dead cells, and the remaining cells were ﬁxed with
methanol. After staining with 1% CV solution, the plates were
thoroughly washed and then the dye was dissolved in 33% acetic
acid. The absorbance of dissolved dyes, corresponding to the
number of viable cells, was measured in triplicates at 540 nm with
a correction at 670 nm, using an automated microplate reader (LKB
5060-006, LKB, Vienna, Austria).
2.3. Detection of NO release
Nitrite accumulation – a measure of NO release, was deter-
mined in cell culture supernatants using the Griess reaction. In
brief, triplicate aliquots of cell-free supernatants were mixed with
an equal volume of Griess reagent (1:1 mixture of 0.1%
naphthylethylenediamine dihydrochloride and 1% sulphanilamide
in 5% H3PO4). The absorbance at 540 nm was determined with a
microplate reader and compared to a standard curve for NaNO2.
2.4. Detection of reactive oxygen species (ROS) generation
For detection of ROS generation dihydrorhodamine 123 (DHR,
Sigma–Aldrich) staining was performed. The cells were incubated
in the presence of 1 mM DHR for 30 min and subsequently treated
as indicated. The ﬂuorescence was acquired via ﬂow cytometry.
2.5. ELISA test for determination of cytokines
Cytokine concentration in cell culture supernatants was
determined by sandwich ELISA using MaxiSorp plates (Nunc,
Rochild, Denmark) and anti-cytokine paired antibodies according
to the manufacturer’s instructions. Samples were analyzed in
duplicates for murine TNF and murine IL-6 (R&D Systems,
Minneapolis, MN). The results were calculated using standard
curves made on the basis of known concentrations of the
appropriate recombinant cytokines.
2.6. Immunoblot
Whole-cell lysates were prepared in a solution containing
62.5 mM Tris–HCl, 2% (w/v) SDS, 10% glycerol, 50 mM dithio-
threitol, 0.01% (w/v) bromophenol blue, 1 mM phenylmethane-
sulfonyl ﬂuoride or phenylmethylsulfonyl ﬂuoride, 1 mg/ml
aprotinine, and 2 mM EDTA (pH 6.8). Samples containing 20 mg
of proteins (measured by Lowry protein assay) were electrophor-
esed on a 12% SDS-polyacrylamide gel. The samples were electro-
transferred to polyvinylidene diﬂuoride membranes at 5 mA/cm2,
using semi-dry blotting system (Fastblot B43, Biorad, Muenchen,Germany). The blots were blocked with 5% (w/v) non-fat dry milk
in PBS with 0.1% Tween-20, and probed with speciﬁc antibodies for
phosphorylated-IkB and b-actin (Cell Signaling Technology,
Boston, MA), followed by incubation with the secondary antibody
(ECL donkey anti-rabbit HRP-linked, GE Healthcare, Buckingham-
shire, England, UK). Detection was performed by the chemilumi-
nescence (ECL, GE Healthcare) and photographs were made by X-
ray ﬁlms (Kodak, Rochester, NY). Densitometry was performed
with Scion Image Alpha 4.0.3.2 (Scion Corporation, Frederick, MD)
and the results are presented as relative densitometry values
(RDV).
2.7. Cytoﬂuorimetry for detection of cell-surface markers
BV2 cells were stained with FITC-conjugated anti-CD40 (BD
Biosciences, San Diego, CA) and PE-conjugated anti-F4/80
(eBioscience, San Diego, CA). Appropriate isotype control anti-
bodies were used where necessary to set gates for cell marker
positivity. Typically, proportion of isotype control antibody-
stained cells was <1%. BV2 cells were analyzed with a CyFlow
Space ﬂow cytometer (Partec, Munster, Germany). Results of
cytoﬂuorimetry are presented as proportion of cells bound by an
appropriate antibody.
2.8. Real-time cell analysis
Cell activation was characterized in real-time by using an
xCELLigence RTCA DP analyzer (Roche Diagnostics, Pleasanton,
CA). BV2 cells were seeded at 1  104 cells into each well of an E-
Plate 16 (Roche Diagnostics). After 60 min of initial adherence, BV2
cells were stimulated and treated as indicated in the results.
Impedance measurements were recorded every minute during the
ﬁrst 3 h of cultivation and then every 15 min overnight. Impedance
measurements were recorded as a combined cellular index of
proliferation, viability, activation and morphology changes.
2.9. Statistical analysis
A Student’s t-test (two-tailed) was performed for statistical
analysis. A P value less than 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Real-time effects on BV2 cells
Impedance measurement in cell cultures is a novel methodolo-
gy that has been shown informative for proliferation, viability,
activity and morphology changes of BV2 cells [20]. BV2 cells were
plated overnight and then stimulated with IFN-g+LPS and
simultaneously treated with various concentrations of EP. As
presented in Fig. 1, BV2 culture impedance increased in response to
IFN-g+LPS, while EP application inhibited impedance in BV2
cultures immediately after the addition of the agent. EP affected
the impedance in a dose dependent manner. Thus, RTCA clearly
shows that EP affects BV2 cell biology in relative short time (min).
3.2. Effects on BV2 viability, IL-6, TNF and NO production
BV2 cells were stimulated with IFN-g+LPS and simultaneously
treated with EP for 10, 20, 30, 60 or 120 min. Then, cell culture
supernatants were removed from the wells and fresh culturing
media without the stimulants and without EP were added in. The
additional cultivation of the cells was performed up to total
incubation time of 24 h. BV2 cells were also stimulated and treated
Fig. 1. RTCA of EP effects on BV2 cells. BV2 cells were cultivated for 22 h and then stimulated with IFN-g+LPS (stim) and simultaneously treated with EP. RTCA was continued
for 10 h. A representative graph is shown.
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till the end of incubation. Continuous presence of 25 mM and
12.5 mM EP signiﬁcantly reduced cell viability of BV2 cells after
24 h of cultivation (Fig. 2A). However, the effect on cell viability
was weaker, yet statistically signiﬁcant, if EP was present in cell
cultures for 120 or 60 min and it was completely absent if EP was
present in cell cultures for 30, 20 or 10 min (Fig. 2A). Supernatants
of the cell cultures collected after 24 h of incubation were analyzed
for IL-6, TNF and nitrite levels. Basal levels of IL-6, TNF and nitrite
were low in un-stimulated cultures (0.06  0.03 ng/ml, un-detect-
able and 1.2  0.3 mM, respectively). IFN-g+LPS induced production
of the cytokines and NO in BV2 cells, and the production was
efﬁciently inhibited by short treatments of stimulated BV2 cells with
EP (Fig. 2B–D). Similar results were obtained if BV2 cells were
additionally stimulated with IFN-g+LPS after initial removal of cell
culture supernatants after 20, 30 or 60 min of the stimulation and EP
treatment (Fig. 3). Importantly, the effects of EP on the cytokines and
NO production were sustained in spite of the additional stimulation
(Fig. 3B–D). Thus, relatively short treatments of BV2 cells with EP
potently inhibited production of IL-6, TNF and NO for prolonged
period of time and had only minor effect on the cell viability.
3.3. Effects on F4/80 and CD40 expression and NFkB activation in BV2
cells
Further, the effects of the short treatments with EP on the
proportion of BV2 cells simultaneously expressing F4/80 and CD40
were determined. Low percentage of un-stimulated BV2 cells
expressed both F4/80 and CD40 (typically less than 5%). The
proportion was markedly increased in IFN-g+LPS-stimulated BV2
cells (Fig. 4A). While continuous presence of EP in 24 h BV2 cultures
potently inhibited percentage of IFN-g+LPS-stimulated BV2 cells
expressing F4/80 and CD40, short-term exposure (1 h and 2 h) to EP
did not (Fig. 4A). The effects of EP on NFkB activation in BV2 cells
were determined via detection of phosphorylated, i.e. inactivated
NFkB inhibitory molecule – IkB. The short time treatments with EP
did not modulate levels of phospho-IkB in IFN-g+LPS-stimulated
BV2 cells (Fig. 4B). Finally, the inﬂuence of EP on ROS generation in
BV2 cells was investigated by DHR staining. There was no effect of EP
on ROS production in IFN-g+LPS-stimulated BV2 cells (Fig. 4C). Thus,
the short exposure of BV2 cells to EP did not affect their ability to
simultaneously express F4/80 and CD40, nor it inhibited NFkB
activation and ROS production in these cells.4. Discussion
It is shown here that activated microglial cells are sensitive to
short exposure to EP. Their ability to produce TNF, IL-6 and NO is
markedly inhibited under the inﬂuence of EP. Still, the effects of the
short-term exposure of microglial cells to EP were not general, as
proportion of the cells expressing CD40 were not affected by the
treatment. Also, microglial cell viability was mostly preserved
under the treatment. Production of TNF, IL-6 and NO by microglia
has been reportedly shown detrimental in various CNS disorders.
For instance, TNF produced by microglia was shown essential for
induction of neuronal cell cycle events, which are toxic for
terminally differentiated neurons in AD [21]. Inhibition of
intracellular trafﬁcking of TNF in microglial cells protected animals
from stroke-like disease [22]. Microglial TNF induced demyelin-
ation in cerebellar organotypic cultures [17]. Overproduction of IL-
6 by microglia was proposed to have a major role in cognitive
decline in AD [23]. NO produced by microglial cells in vitro in
response to heat shock protein 60 or IFN-g+LPS was identiﬁed as
the major neurotoxic molecule [24,25]. Inducible NO synthase
positive microglial cells were suggested to promote axoglial
disruption and consequent axonal injury and neurodegeneration in
MS and PD [26]. Thus, the observed powerful inhibition of IL-6, TNF
and NO production in microglia under the inﬂuence of EP is a good
indication of an anti-neuroinﬂammatory potency of this agent. As
microglial cells are not sole producers of these cytokines and NO in
the inﬂamed CNS, previously reported inhibitory effect of EP on
their production in other relevant cells, such as astrocytes [19,27]
additionally supports an idea of EP as a prospective anti-
neuroinﬂammatory drug. Indeed, EP has already been shown
efﬁcient in models of various CNS disorders, including ischemia/
reperfusion [13], intracerebral hemorrhage-induced brain injury
[14], traumatic brain injury [15], and EAE [19]. Also, it was shown
protective against biochemical neurological insults, such as 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine [16], LPS [17], and 3-
nitropropionic acid [18].
Our ﬁndings that exposure of microglial cells to EP as short as
20 min has sustained effect on their ability to produce inﬂamma-
tory mediators is highly relevant for the pharmacological
properties of the agent. This feature of EP is of special value
having in mind relatively high concentrations of the agent
necessary for the efﬁcient in vivo application. For instance,
protective effects of EP in models of neuroinﬂammatory and
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Fig. 2. Effects of EP on BV2 cell viability and production of IL-6, TNF and NO. BV2
cells were stimulated with IFN-g+LPS and simultaneously treated with EP for the
indicated time periods. Subsequently, cell culture supernatants were removed and
fresh medium was added to the cultures. Incubation was continued to the ﬁnal time
period of 24 h. Then, cell viability (A), IL-6 (B), TNF (C) and NO (D) levels were
determined. Data from three independent experiments are presented as mean  SD.
*P<0.05, statistically signiﬁcant difference to EP-untreated (0) cultures.
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Fig. 3. Effects of EP on BV2 cell viability and production of IL-6, TNF and NO in the
cultures that were stimulated additionally. BV2 cells were stimulated with IFN-
g+LPS and simultaneously treated with EP for the indicated time periods.
Subsequently, cell culture supernatants were removed and fresh medium
containing IFN-g+LPS was added to the cultures. Incubation was continued to
the ﬁnal time period of 24 h. Then, cell viability (A), IL-6 (B), TNF (C) and NO (D)
levels were determined. Data from three independent experiments are presented as
mean  SD. *P < 0.05, statistically signiﬁcant difference to EP-untreated (0) cultures.
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Fig. 4. Effects of EP on CD40 and F4/80 expression, activation of NFkB and ROS generation in BV2 cells. BV2 cells were stimulated with IFN-g+LPS and simultaneously treated
with EP (12.5 mM) for the indicated time periods. For detection of the cells expressing CD40 and F4/80 (A), cell culture supernatants were removed, fresh medium was added
to the cultures and the incubation was continued to the ﬁnal time period of 24 h. Detection of phospho-IkB (B) and ROS detection with DHR (C) were performed at indicated
time points. Data from two independent experiments are presented as mean  SD. *P<0.05, statistically signiﬁcant difference to EP-untreated (0) cultures.
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3.87 mg/kg to 300 mg/kg [15,16,19]. EP is generally considered to
be a safe and well tolerated agent in its in vivo applications,
including human studies [7,10]. Thus, high amounts of EP do not
seem to be obstacle for its application. As an illustration, in an US-
based clinical trial (the only ﬁnished Phase II trial on EP so far), six
doses of 7.5 g of EP were administered to high-risk patients
undergoing cardiac surgery intravenously during 36 h (360 mg/kg/
day) [28]. Still, the sustained effects of EP in vitro presented in this
study imply that there is no need for frequent or continuous
application of EP. This is especially important considering short
half-life time of pyruvates in biological systems, e.g. approximately
10 min for sodium pyruvate in the circulation [29]. Although EP is
more stable in the circulation (Fink, 2007), it is readily metabolized
to pyruvate within the cells [30]. EP is fairly soluble in lipids and
therefore it is easily transported across cell membrane, but also
across blood–brain barrier [31]. Once EP is metabolized into
pyruvate, it is entering mitochondria and Krebs cycle having the
half-life time of approximately 2 min within the CNS [32]. Thus,
durability of EP effects seems to be very important for its in vivo
efﬁcacy. Indeed, remarkable effects of EP in models of MS and PD
were obtained with only one application per day, or even one
application in two days [16,19]. Further studies should explore if
the efﬁciency of short time exposure to EP is speciﬁc for microglial
cells, or it is a more general phenomenon. Also, in vivo evaluation of
the phenomenon is foreseen.
Although the short exposure of microglial cells to EP potently
inhibited their production of IL-6, TNF and NO, it was inefﬁcient in
modulating NFkB activation at the same time. Importantly, it was
previously reported that expression of iNOS, TNF and IL-6 in glial
cells stimulated with IFN-g+LPS or with LPS was dependent on
rapid activation of NADPH oxidase(Phox)-derived reactive oxygen
species (ROS) and subsequent activity of STAT siganling
[33,34]. Thus, the observed effects of EP on the production of
the inﬂammatory molecules in NFkB independent way may be
explained by direct redox activity of EP against ROS. Still, inhibitory
effect of EP on ROS generation in BV2 cells was not detected by DHR
staining in our experiments. Nevertheless, the possibility that the
observed effects of EP on cytokine and NO production in BV2 cells
are ROS-related should not be ruled out before more sensitive ROS
detection tests are performed in future studies.
In conclusion, inappropriate functions of microglial cells play a
central role in pathogenesis of various CNS disorders. Here, we
show that short-time exposure of microglial cells to ethyl pyruvate
in vitro restrains production of proinﬂammatory molecules inthese cells for prolonged period. These ﬁndings are important for
understanding the efﬁciency of EP as an agent effective against
various CNS disorders. Also, they represent a novel step toward
potential therapeutic application of EP.
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